Category: Press Release - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor

Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor

Post published:April 8, 2021
Post category:Press Release

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

Post published:April 8, 2021
Post category:Press Release

atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders

atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders

Post published:April 7, 2021
Post category:Press Release

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Post published:April 7, 2021
Post category:Press Release

Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical

Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical

Post published:April 7, 2021
Post category:Press Release

Lobe Sciences Appoints Ilan Hayman to Advisory Board

Lobe Sciences Appoints Ilan Hayman to Advisory Board

Post published:April 6, 2021
Post category:Press Release

Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

Post published:April 6, 2021
Post category:Press Release

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

Post published:April 5, 2021
Post category:Press Release

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

Post published:April 5, 2021
Post category:Press Release

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

Post published:April 2, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.